

L8 ANSWER 5 OF 99 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS
INC.

AN 2001:527225 BIOSIS

DN PREV200100527225

TI Enumeration of CD8+ T cell precursors against a
mutated HSP70 peptide in healthy and renal cell
carcinoma patients.

AU Mar, W. A. (1); Triebel, F. (1)

CS (1) Department of Immunology, Institut Gustave Roussy, Villejuif France

SO Journal of Investigative Medicine, (January, 2000) Vol. 48, No. 1, pp.
42A. print.

Meeting Info.: Meeting of the American Federation for Medical Research,
Western Region Carmel, California, USA February 09-12, 2000

ISSN: 1081-5589.

DT Conference

LA English

SL English

L8 ANSWER 3 OF 99 MEDLINE

AN 2001100729 MEDLINE

DN 21036713 PubMed ID: 11196165

TI Human heat shock protein 70 peptide complexes specifically
activate antimelanoma T cells.

AU Castelli C; Ciupitu A M; Rini F; Rivoltini L; Mazzocchi A; Kiessling R;
Parmiani G

CS Unit of Immunotherapy of Human Tumors, Istituto Nazionale per lo Studio e
la Cura dei Tumori, Milan, Italy.

SO CANCER RESEARCH, (2001 Jan 1) 61 (1) 222-7.

Journal code: CNF. ISSN: 0008-5472.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200102

ED Entered STN: 20010322

Last Updated on STN: 20010322

Entered Medline: 20010201

L8 ANSWER 36 OF 99 USPATFULL

AN 2001:188410 USPATFULL

TI Complexes of peptide-binding fragments of heat shock proteins
and their use as immunotherapeutic agents

IN Srivastava, Pramod K., Avon, CT, United States

PI US 2001034042 A1 20011025

AI US 2001-759010 A1 20010112 (9)

RLI Continuation-in-part of Ser. No. US 2000-488393, filed on 20 Jan 2000,

PENDING
DT Utility
FS APPLICATION
LN.CNT 3685
INCL INCLM: 435/068.100
INCLS: 514/012.000
NCL NCLM: 435/068.100
NCLS: 514/012.000
IC [7]
ICM: C12P021-06
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 31 OF 99 USPATFULL
AN 2001:214659 USPATFULL
TI Compositions and methods for eliciting an immune response using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
IN Srivastava, Pramod K., Riverdale, NY, United States
PA Fordham University, Bronx, NY, United States (U.S. corporation)
PI US 6322790 B1 20011127
AI US 1998-135712 19980818 (9)
RLI Division of Ser. No. US 1997-796316, filed on 7 Feb 1997, now patented, Pat. No. US 5830464
DT Utility
FS GRANTED
LN.CNT 2321
INCL INCLM: 424/193.100
INCLS: 424/195.110; 424/196.110; 424/197.110; 424/093.700; 424/093.710; 435/325.000; 435/377.000; 435/383.000; 435/384.000; 435/385.000; 514/002.000; 530/350.000; 530/806.000; 530/807.000
NCL NCLM: 424/193.100
NCLS: 424/093.700; 424/093.710; 424/195.110; 424/196.110; 424/197.110; 435/325.000; 435/377.000; 435/383.000; 435/384.000; 435/385.000; 514/002.000; 530/350.000; 530/806.000; 530/807.000
IC [7]
ICM: A01N063-00
ICS: A01N037-18; A61K039-39; C12N005-08; C07K001-00
EXF 424/193.1; 424/195.11; 424/196.11; 424/197.11; 424/93.7; 424/93.71; 435/325; 435/377; 435/383; 435/384; 435/386; 514/2; 530/350; 530/806; 530/807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 81 OF 99 USPATFULL
AN 2000:134754 USPATFULL

L9 ANSWER 1 OF 92 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS
INC.

AN 2001:527225 BIOSIS

DN PREV200100527225

TI Enumeration of CD8+ T cell precursors against a
mutated HSP70 peptide in healthy and renal
cell carcinoma patients.

AU Mar, W. A. (1); Triebel, F. (1)

CS (1) Department of Immunology, Institut Gustave Roussy, Villejuif France

SO Journal of Investigative Medicine, (January, 2000) Vol. 48, No. 1, pp.

42A. print.

Meeting Info.: Meeting of the American Federation for Medical Research,
Western Region Carmel, California, USA February 09-12, 2000

ISSN: 1081-5589.

DT Conference

LA English

SL English

CC General Biology - Symposia, Transactions and Proceedings of Conferences,
Congresses, Review Annuals *00520

Cytology and Cytochemistry - Animal *02506

Cytology and Cytochemistry - Human *02508

Biochemical Studies - General *10060

Neoplasms and Neoplastic Agents - Immunology *24003

Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic
Effects *24004

Immunology and Immunochemistry - General; Methods *34502

Immunology and Immunochemistry - Immunopathology, Tissue Immunology
*34508

BC Hominidae 86215

Muridae 86375

IT Major Concepts

Biochemistry and Molecular Biophysics; Immune System (Chemical
Coordination and Homeostasis); Tumor Biology

IT Parts, Structures, & Systems of Organisms

CD8-positive T cell precursors: enumeration, immune
system; antigen presenting cells: immune system; peripheral blood
lymphocytes: blood and lymphatics, immune system

IT Diseases

renal cell carcinoma: neoplastic disease, urologic disease

IT Chemicals & Biochemicals

HSP70 peptide [heat shock
protein 70 peptide]: immunogenicity,
mutated; cancer vaccine: vaccine

IT Alternate Indexing

Kidney Neoplasms (MeSH); Carcinoma, Renal Cell (MeSH)

IT Miscellaneous Descriptors

Meeting Abstract

ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae:
Rodentia, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name

T2 cell line (Muridae): mouse antigen presenting cells; human
(Hominidae)

ORGN Organism Superterms

Animals; Chordates; Humans; Mammals; Nonhuman Mammals; Nonhuman
Vertebrates; Primates; Rodents; Vertebrates

TI Methods for generating cytotoxic T cells in vitro
IN Srivastava, Pramod K., Riverdale, NY, United States
Binder, Robert, Bronx, NY, United States
Blachere, Nathalie E., Bronx, NY, United States
PA Fordham University, Bronx, NY, United States (U.S. corporation)
PI US 6130087 20001010
AI US 1996-726967 19961007 (8)
DT Utility
FS Granted
LN.CNT 1534
INCL INCLM: 435/372.300
INCLS: 435/375.000; 435/377.000
NCL NCLM: 435/372.300
NCLS: 435/375.000; 435/377.000
IC [7]
ICM: C12N005-06
ICS: C12N005-08
EXF 435/372.3; 435/377; 435/375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 78 OF 99 USPATFULL
AN 2000:141883 USPATFULL
TI Compositions and methods using complexes of heat shock protein 70 and
antigenic molecules for the treatment and prevention of neoplastic
diseases
IN Srivastava, Pramod K., Riverdale, NY, United States
PA Fordham University, Bronx, NY, United States (U.S. corporation)
PI US 6136315 20001024
AI US 1998-150204 19980909 (9)
RLI Division of Ser. No. US 1995-527391, filed on 13 Sep 1995, now patented,
Pat. No. US 5837251
DT Utility
FS Granted
LN.CNT 2358
INCL INCLM: 424/193.100
INCLS: 424/184.100; 424/277.100; 424/085.100; 424/085.200; 424/085.500;
424/085.600; 424/085.700; 530/403.000; 530/417.000; 435/810.000;
436/543.000; 514/002.000
NCL NCLM: 424/193.100
NCLS: 424/085.100; 424/085.200; 424/085.500; 424/085.600; 424/085.700;
424/184.100; 424/277.100; 435/810.000; 436/543.000; 514/002.000;
530/403.000; 530/417.000
IC [7]
ICM: A61K039-00
ICS: A61K039-002; A61K039-38; A61K039-385

EXF 424/193.1; 424/277.1; 424/184.1; 424/85.1; 424/85.2; 424/85.5; 424/85.6;
424/85.7; 435/810; 436/543; 514/2; 530/403; 530/417
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

BC Hominidae *86215
IT Major Concepts
 biochemistry and Molecular Biophysics; Immune System (Chemical Coordination and Homeostasis); Oncology (Human Medicine, Medical Sciences); Pathology; Reproductive System (Reproduction); Urinary System (Chemical Coordination and Homeostasis)
IT Miscellaneous Descriptors
 AUTOLOGOUS DENDRITIC CELLS; HLA-A0201-SPECIFIC **PEPTIDE**; MALE; **NEOPLASTIC** DISEASE; ONCOLOGY; PATIENT; PHASE I CLINICAL TRIAL; PROSTATE **CANCER**; PROSTATE SPECIFIC MEMBRANE ANTIGEN; REPRODUCTIVE SYSTEM DISEASE/MALE; T-CELL THERAPY; THERAPEUTIC METHOD; UROLOGIC DISEASE; UROLOGY
ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
 human (Hominidae)
ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates

L14 ANSWER 531 OF 577 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1996:64047 BIOSIS
DN PREV199698636182
TI A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma: An Illinois **Cancer** Center Study.
AU Gradishar, William J. (1); Vogelzang, Nicholas J.; Kilton, Lary J.; Leibach, Steven J.; Rademaker, Alfred W.; French, Suzanne; Benson, Al B., III
CS (1) Northwestern Univ. Med. Sch., 233 East Erie, Suite 700, Chicago, IL 60611 USA
SO Investigational New Drugs, (1995) Vol. 13, No. 2, pp. 171-174. ISSN: 0167-6997.
DT Article
LA English
AB Echinomycin, a cyclic **peptide** in the family of quinoxaline antibiotics, was evaluated in patients with metastatic, soft tissue sarcoma not previously **treated** for metastatic disease. The starting dose of echinomycin was 1,200 mcg/m² administered intravenously, once weekly times 4, followed by a two-week break. The protocol design called for dose escalation on subsequent cycles of therapy, but because of significant toxicity, dose escalation occurred in only 5 of 25 **treatment** cycles. Severe nausea and vomiting was the most common toxicity. No clinical responses were observed in the 12 evaluable patients. Echinomycin at this dose and schedule is inactive in metastatic soft tissue sarcoma.

CC Biochemical Studies - General 10060
 Pathology, General and Miscellaneous - Therapy *12512
 Digestive System - Pathology *14006
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System *15008
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Pathology *18006
 Pharmacology - Clinical Pharmacology *22005
 Pharmacology - Connective Tissue, Bone and Collagen - Acting Drugs *22012
 Toxicology - Pharmacological Toxicology *22504
 Neoplasms and Neoplastic Agents - Pathology; Clinical Aspects; Systemic Effects *24004
 Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy *24008

BC Hominidae *86215
IT Major Concepts
 Blood and Lymphatics (Transport and Circulation); Gastroenterology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical Sciences); Pathology; Pharmacology; Skeletal System (Movement and Support); Toxicology
IT Chemicals & Biochemicals
 ECHINOMYCIN

IT Miscellaneous Descriptors
 ANTINEOPLASTIC-DRUG; ECHINOMYCIN; **INEFFECTIVE**
 TREATMENT; NAUSEA; TOXICITY; VOMITING
ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
 human (Hominidae)
ORGN Organism Superterms
 animals; chordates; humans; mammals; primates; vertebrates
RN 512-64-1 (ECHINOMYCIN)

=> d 511, 512, 519, 524, 531 114 all

L14 ANSWER 511 OF 577 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:131347 BIOSIS
DN PREV199900131347
TI **Peptides** as drugs.
AU Edwards, C. M. B.; Cohen, M. A.; Bloom, S. R.
CS ICSM Endocrine Unit, Hammersmith Hosp., London UK
SO QJM, (Jan., 1999) Vol. 92, No. 1, pp. 1-4.
ISSN: 0033-5622.
DT Editorial
LA English
CC Pharmacology - General *22002
Biochemical Studies - General *10060
Pathology, General and Miscellaneous - Therapy *12512
Metabolism - Metabolic Disorders *13020
Nutrition - Malnutrition; Obesity *13203
Digestive System - General; Methods *14001
Blood, Blood-Forming Organs and Body Fluids - General; Methods *15001
Urinary System and External Secretions - General; Methods *15501
Endocrine System - General *17002
Nervous System - General; Methods *20501
BC Hominidae 86215
IT Major Concepts
Pharmacology
IT Diseases
acromegaly: bone disease, endocrine disease/pituitary,
treatment; anemia: blood and lymphatic disease,
treatment; chronic renal **failure: treatment**
, urologic disease; diabetes: endocrine disease/pancreas,
treatment, metabolic disease; gastro-enteropancreatic endocrine
tumors: digestive system disease, **treatment**,
neoplastic disease, endocrine disease; hypoglycemia: metabolic
disease, **treatment**; multiple sclerosis: immune system
disease, nervous system disease; neutropenia: blood and lymphatic
disease, **treatment**; obesity: nutritional disease,
treatment; Alzheimer's disease: behavioral and mental
disorders, **treatment**, nervous system disease; Parkinson's
disease: nervous system disease, **treatment**
IT Chemicals & Biochemicals
copolymer 1; glucagon-like **peptide**-1: endogenous hormone,
metabolic - drug; granulocyte macrophage-colony stimulating factor
stimulate: hematologic - drug, human growth factor; granulocyte-colony
stimulating factor: hematologic - drug, human growth factor; human
erythropoietin: hematologic - drug; insulin: antidiabetic - drug;
interferon beta-1a: immunologic - drug; interferon beta-1b: immunologic
- drug; leptin: adipose **peptide** hormone, anorexic - drug;
nerve growth factor: neuroprotectant - drug; octreotide: hormone -
drug, somatostatin analogue; **peptide** antibiotics;
peptides: administration mode, therapeutic use
IT Alternate Indexing
Acromegaly (MeSH); Alzheimer Disease (MeSH); Anemia (MeSH); Diabetes
Mellitus (MeSH); Hypoglycemia (MeSH); Kidney **Failure**, Chronic
(MeSH); Multiple Sclerosis (MeSH); Neutropenia (MeSH); Obesity (MeSH);
Parkinson Disease (MeSH)
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae): patient
ORGN Organism Superterms
Animals; Chordates; Humans; Mammals; Primates; Vertebrates
RN 9004-10-8 (INSULIN)
9007-92-5 (GLUCAGON)

169494-85-3 (LEPTIN)
83150-76-9 (OCTREOTIDE)
11096-26-7 (ERYTHROPOIETIN)

L14 ANSWER 512 OF 577 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 1998:513175 BIOSIS

DN PREV199800513175

TI Immunization with a **peptide** epitope (p369-377) from HER-2/neu leads to **peptide**-specific cytotoxic T lymphocytes that **fail** to recognize HER-2/neu+ tumors.

AU Zaks, Tal Z. (1); Rosenberg, Steven A.

CS (1) Surg. Branch, Natl. Cancer Inst., Build. 10, Room 2B-46, NIH, Bethesda, MD 20892-1502 USA

SO Cancer Research, (Nov. 1, 1998) Vol. 58, No. 21, pp. 4902-4908. ISSN: 0008-5472.

DT Article

LA English

AB The oncogene HER-2/neu is genetically amplified and overexpressed in a large number of human adenocarcinomas and has been implicated in the tumorigenic phenotype. Although it is a nonmutated self-protein, it is barely detectable in adult tissues, and immune responses toward it have been described in a number of patients. It is, thus, an attractive candidate antigen for the immunotherapy of **cancer** patients. HLA-A2+ patients with metastatic breast, ovarian, or colorectal adenocarcinomas that overexpressed HER-2/neu were immunized with the HLA-A2-binding epitope p369-377 (p369). Patients were **treated** by repeated immunization with 1 mg of p369 in Freund's incomplete adjuvant every 3 weeks. Peripheral blood mononuclear cells were collected prior to immunization and following two and four immunizations and were stimulated in vitro with **peptide** and assayed for **peptide** and tumor recognition. In three of four patients, **peptide**-specific CTLs were detected in post- but not preimmunization blood. These CTLs recognized **peptide**-pulsed target cells at **peptide** concentrations of 100 ng/ml yet **failed** to react with a panel of HLA-A2+ HER-2/neu+ tumor lines. In addition, infecting HLA-A2+ cells with recombinant vaccinia virus encoding HER-2/neu or up-regulating HLA-A2 with IFN-gamma in HER-2/neu+ cells also **failed** to confer reactivity by p369-reactive T-cells. A T-cell response to the HLA-A2 binding epitope p369 can be easily generated by immunizing patients with **peptide** in Freund's incomplete adjuvant. However, the CTLs **failed** to react with HER-2/neu+ tumor cells. Further studies are needed to determine whether and how HER-2 might serve as an antigen for tumor immunotherapy.

CC Neoplasms and Neoplastic Agents - General *24002

Cytology and Cytochemistry - Human *02508

Biochemical Studies - General *10060

Pathology, General and Miscellaneous - Therapy *12512

Digestive System - General; Methods *14001

Blood, Blood-Forming Organs and Body Fluids - General; Methods *15001

Reproductive System - General; Methods *16501

Pharmacology - General *22002

Immunology and Immunochemistry - General; Methods *34502

BC Hominidae 86215

IT Major Concepts

Clinical Immunology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical Sciences)

IT Parts, Structures, & Systems of Organisms

cytotoxic T lymphocytes: blood and lymphatics, immune system, **peptide**-specific

IT Diseases

breast adenocarcinoma: HER-2-neu-positive, reproductive system disease/female, **neoplastic** disease; colorectal

adenocarcinoma: HER-2-neu-positive, digestive system disease, **neoplastic** disease; ovarian adenocarcinoma: HER-2-neu-positive,

neoplastic disease, reproductive system disease/female
 IT Chemicals & Biochemicals
 HER-2-neu **peptide** epitope: immunologic - drug, p369-377
 IT Methods & Equipment
 immunization: immunologic method
 ORGN Super Taxa
 Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
 ORGN Organism Name
 human (Hominidae): female, male, patient
 ORGN Organism Superterms
 Animals; Chordates; Humans; Mammals; Primates; Vertebrates

L14 ANSWER 519 OF 577 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1997:305850 BIOSIS
 DN PREV199799613653

TI Analysis of the T cell response to tumor and viral **peptide**
 antigens by an IFN gamma-ELISPOT assay.

AU Scheibenbogen, Carmen (1); Lee, Kang-Hun; Stevanovic, Stefan; Witzens,
 Mathias; Willhauck, Martina; Waldmann, Volker; Naeher, Helmut; Rammensee,
 Hans-Georg; Keilholz, Ulrich

CS (1) Med. Klin. Poliklin. V, Dep. Hematol./Oncol., Hospitalstr. 3, 69115
 Heidelberg Germany

SO International Journal of Cancer, (1997) Vol. 71, No. 6, pp. 932-936.
 ISSN: 0020-7136.

DT Article

LA English

AB We have established a sensitive ELISPOT assay measuring interferon gamma
 (IFN gamma) release on a single-cell basis to detect influenza
peptide-specific CD8+ T cells in uncultured peripheral blood
 mononuclear cells (PBMC). Using this method, we studied the T cell
 response to HLA-A1 and HLA-A2.1 binding **peptide** epitopes derived
 from the MAGE-1 and MAGE-3 proteins, from the melanoma-associated antigens
 tyrosinase, Melan-A/MART-1 and gp100, and from influenza proteins in stage
 IV melanoma patients and healthy controls. In 18 of 24 HLA-A2-positive
 donors (75%), but only in 9 of 25 HLA-A2positive melanoma patients (36%) T
 cells reactive with the influenza matrix **peptide** were
 demonstrated ($p = 0.007$). T cells responding to one or several of the
 melanoma-associated **peptides** were detected in 5 of 25
 HLA-A2-positive patients with metastatic melanoma. Four of these 5
 patients had been **treated** with interleukin-2- and
 IFN-alpha-containing therapy. Two of the 24 healthy donors had T cells
 reactive with the MART-1 27-3S **peptide**. No reactivity with the
 HLA-A1-binding **peptides** from MAGE-1 or MAGE-3 was detected in
 any of the HLA-A1-positive healthy controls or melanoma patients. These
 results show that the IFN-gamma-ELISPOT assay is suitable to determine
 quantitatively T cells reactive with melanoma-associated and influenza
peptide epitopes in uncultured PBMC. The **failure** to
 detect T cells responding to influenza in many melanoma patients with
 progressive disease may indicate an impairment of their T cell function.

CC Cytology and Cytochemistry - Human 02508
 Biochemical Methods - Proteins, Peptides and Amino Acids 10054
 Biochemical Methods - Carbohydrates 10058
 Biochemical Studies - Proteins, Peptides and Amino Acids 10064
 Biochemical Studies - Carbohydrates 10068
 Anatomy and Histology, General and Comparative - Regeneration and
 Transplantation *11107
 Metabolism - Proteins, Peptides and Amino Acids *13012
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies *15004
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and
 Reticuloendothelial System *15008
 Neoplasms and Neoplastic Agents - Immunology *24003
 Tissue Culture, Apparatus, Methods and Media 32500
 Virology - Animal Host Viruses *33506
 Immunology and Immunochemistry - General; Methods 34502

Immunology and Immunochemistry - Bacterial, Viral and Fungal *34504
Immunology and Immunochemistry - Immunopathology, Tissue Immunology
*34508
Medical and Clinical Microbiology - Virology *36006
BC Hominidae *86215
IT Major Concepts
Blood and Lymphatics (Transport and Circulation); Clinical Immunology
(Human Medicine, Medical Sciences); Immune System (Chemical
Coordination and Homeostasis); Metabolism; Microbiology; Oncology
(Human Medicine, Medical Sciences); Physiology
IT Miscellaneous Descriptors
BLOOD AND LYMPHATICS; ELISPOT ASSAY; HLA HISTOCOMPATIBILITY ANTIGEN
RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL METHOD; IMMUNOLOGY; INFLUENZA
VIRAL **PEPTIDE** RESPONSE; INTERFERON-GAMMA RELEASE; MELANOMA;
MELANOMA ANTIGEN RESPONSE; **NEOPLASTIC** DISEASE; ONCOLOGY;
PATIENT; T-CELLS
ORGN Super Taxa
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia
ORGN Organism Name
human (Hominidae)
ORGN Organism Superterms
animals; chordates; humans; mammals; primates; vertebrates

L14 ANSWER 524 OF 577 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1997:68076 BIOSIS
DN PREV199799367279
TI Phase I clinical trial: T-cell therapy for prostate **cancer** using
autologous dendritic cells pulsed with HLA-A0201-specific **peptides**
from prostate-specific membrane antigen.
AU Murphy, G. (1); Tjoa, B.; Ragde, H.; Kenny, G.; Boynton, A.
CS (1) Pacific Northwest Cancer Foundation, Northwest Hosp., 120 Northgate
Plaza, Suite 205, Seattle, WA 98125 USA
SO Prostate, (1996) Vol. 29, No. 6, pp. 371-380.
ISSN: 0270-4137.
DT Article
LA English
AB BACKGROUND. Conventional **treatment** for metastatic prostate
cancer have **failed** to demonstrate curative potential in
all patients. Investigations involving the role of T-cell immunity in the
clearance of **neoplastic** cells are now available. Development of
T-cell immunotherapy may give a new approach to the **treatment** of
advanced metastatic prostate **cancer**. METHODS. A phase I clinical
trial assessing the administration of autologous dendritic cells (DC)
pulsed with HLA-A0201-specific prostate-specific membrane antigen (PSMA)
peptides were conducted. Participants were divided into five
groups receiving four or five infusions of **peptides** alone
(PSM-P1 or PSM-P2; groups 1 and 2, respectively, autologous DC (group 3),
or DC pulsed with PSM-P1 or P2 (groups 4 and 5, respectively. RESULTS. No
significant toxicity was observed in all five groups. Cellular response
against PSM-P1 and -P2 was observed in HLA-A2+ patients infused with DC
pulsed with PSM-P1 or -P2 (groups 4 and 5), respectively. An average
decrease in PSA was detected only in group 5. Seven partial responders
were identified based on NPCP criteria + PSA. CONCLUSIONS. Infusions of
test substances were well tolerated by all study participants. Detection
of cellular response and decrease in PSA level in some patients who
received DC pulsed with PSM-P2 indicate this method's potential in
prostate **cancer** therapy.
CC Biochemical Studies - General *10060
Pathology, General and Miscellaneous - General *12502
Pathology, General and Miscellaneous - Therapy *12512
Urinary System and External Secretions - General; Methods *15501
Reproductive System - General; Methods *16501
Neoplasms and Neoplastic Agents - General *24002
Immunology and Immunochemistry - General; Methods *34502